News

Aquinnah will use the grants to advance the development of lead compounds focusing on the pathophysiology of TDP-43, found in approximately 90% of cases of ALS. ALS is

The goal of the "CRISPR/Cas9 Genome-Wide sgRNA Library Screening Platform" grant is to develop a validated set of reagents that can be used for specific targeted disruption of

Iclaprim is designed to be effective against multi-drug resistant bacteria. The company requested QIDP designation for Iclaprim for two serious and life threatening infections, HABP and acute bacterial

In March this year, the company secured approval from the US Food and Drug Administration (FDA) for Saphris for the acute treatment of manic or mixed episodes associated

Dysport is now approved to treat ULS in adults to decrease the severity of increased muscle tone in elbow flexors, wrist flexors and finger flexors. The company said

About 360 patients with DES will be included in the multicenter, randomized, double-masked Phase IIb/III trial, which will evaluate the efficacy and superiority of GBT-201 compared to placebo.

Amoun is a major company in Egypt’s pharmaceutical sector and owns brands in therapeutic areas such as anti-hypertensives, broad-spectrum antibiotics and anti-diarrheals. Currently, Amoun expects to reach EGP1.75bn

C2N-8E12 is a humanized antibody that targets the tau protein found in neurofibrillary tangles in the brain of patients with tauopathies such as PSP and Alzheimer’s disease (AD).

AstraZeneca has completed the divestment of non-US global rights of its gastroenterology drug Entocort to Tillotts Pharma (Tillotts), part of the Zeria Group, for $215m. Entocort (budesonide) is